Hrvacević R, Veljancić Lj, Vujanić S, Radojević M, Aleksić S, Marić M
Vojnosanit Pregl. 1999 Nov-Dec;56(6):619-24.
beta 2-microglobulin (beta 2 m) is the major constituent of amyloid fibrils in dialysis-related amyloidosis (DRA), which is considered to be one of the most severe adverse effect of long-term dialysis. In this study we evaluated the efficiency of beta 2 m removal during different dialysis procedures. A total of 45 patients undergoing hemodialysis were divided in five groups: cuprophane dialysis (n = 10), high-flux polysulphone dialysis (n = 10), postdilutional hemodiafiltration (n = 10), conventional postdilutional hemofiltration (n = 10) and predilutional on-line hemofiltration (n = 5). Serum level of beta 2 m was determined before and after different procedures using ELISA. In the group of patients on cuprophane dialysis was registered an elevation of beta 2 m and of 16.8 +/- 11.4% on the average. Serum level of beta 2 m was decreased following all other procedures on the average of 40.7 +/- 16.4% after high-flux polysulphone dialysis, 42.0 +/- 13.7% after conventional hemofiltration, 64.7 +/- 9% after hemodiafiltration and 67.9 +/- 10.1% after predilutional hemofiltration. The best removal of serum beta 2 m was realized by predilutional hemofiltration. Also, we have noticed that patients treated with high-flux synthetic membranes in the longer time-period have lower predyalisis value of beta 2 m compared to patients treated with cuprophane membrane. Further long-term studies will be necessary to conclude whether these procedures could be successful prophylactic and/or therapeutic regimen for dialysis-related amyloidosis.
β2-微球蛋白(β2m)是透析相关性淀粉样变(DRA)中淀粉样纤维的主要成分,DRA被认为是长期透析最严重的不良反应之一。在本研究中,我们评估了不同透析程序中β2m的清除效率。共有45例接受血液透析的患者被分为五组:铜仿膜透析(n = 10)、高通量聚砜膜透析(n = 10)、后稀释血液透析滤过(n = 10)、传统后稀释血液滤过(n = 10)和前稀释在线血液滤过(n = 5)。使用酶联免疫吸附测定法(ELISA)在不同程序前后测定血清β2m水平。在铜仿膜透析组中,β2m平均升高了16.8±11.4%。在所有其他程序后,血清β2m水平均下降,高通量聚砜膜透析后平均下降40.7±16.4%,传统血液滤过后下降42.0±13.7%,血液透析滤过后下降64.7±9%,前稀释血液滤过后下降67.9±10.1%。前稀释血液滤过对血清β2m的清除效果最佳。此外,我们还注意到,与使用铜仿膜治疗的患者相比,长时间使用高通量合成膜治疗的患者透析前β2m值较低。是否这些程序能够成功地用于预防和/或治疗透析相关性淀粉样变,还需要进一步的长期研究来得出结论。